"These studies reinforce the importance of CancerTYPE ID as an integral part of metastatic cancer patient management," Ding said. "Metastatic solutions require knowing the site of origin and the use of predictive biomarkers to get patients on the right therapy the first time. bioTheranostics offers a complete solution for metastatic cancer with CancerTYPE ID and PRÉCIS biomarkers-providing a full integration of molecular diagnostics."
The study, "Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients with Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research Institute," can be accessed here. Preliminary results were presented at the American Society of Clinical Oncology meeting in June.
Ad Statistics
Times Displayed: 22687
Times Visited: 478 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
About bioTheranostics
bioTheranostics is the leading solution provider for metastatic cancer management, leveraging its unique expertise in expression profiling to develop a growing array of molecular diagnostic tests for cancer patients. The company operates a CLIA-certified, CAP-accredited diagnostic laboratory to perform its proprietary tests: the CancerTYPE ID® molecular classification test; PRÉCISSM Precision Medicine, which includes biomarker profiles for non-small cell lung and colorectal cancers; and Breast Cancer IndexSM, which quantifies risk of recurrence of estrogen receptor positive, lymph node negative breast cancer. bioTheranostics, a bioMérieux company, is based in San Diego. Learn more www.biotheranostics.com.
Back to HCB News
